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Abstract  
Background 
During the five decades since their discovery, filoviruses of four species have caused human 
hemorrhagic fever outbreaks: Marburg (MARV) marburgvirus, and Zaire (EBOV), Sudan (SUDV) 
and Bundybugyo (BDBV) ebolaviruses. The largest, devastating EBOV epidemic in West Africa in 
2014-16, has been followed by outbreaks of MARV in Uganda, 2017, and EBOV in Democratic 
Republic of Congo, 2018, emphasizing the need to develop preparedness to diagnose all filoviruses.  
Objectives 
The aim of this study was to optimize a new filovirus RT-qPCR to detect all filoviruses, define its 
limits of detection (LOD) and perform a field evaluation with outbreak samples.  
Study design 
A pan-filovirus RT-qPCR targeting the L gene was developed and evaluated within the 
EbolaMoDRAD (Ebola virus: modern approaches for developing bedside rapid diagnostics) project. 
Specificity and sensitivity were determined and the effect of inactivation and PCR reagents (liquid 
and lyophilized format) were tested.   
Results 
The LODs for the lyophilized pan-filovirus L-RT-qPCR assay were 9.4 copies per PCR reaction for 
EBOV, 9.9 for MARV, 1151 for SUDV, 65 for BDBV and 289 for Taï Forest virus. The test was set 
at the Pasteur Institute, Dakar, Senegal, and 83 Ebola patient samples, with viral load ranging from 5 
to 5 million copies of EBOV per reaction, were screened. The results for the patient samples were in 
100% concordance with the reference EBOV-specific assay. 
Discussion 
Overall, the assay showed good sensitivity and specificity, covered all filoviruses known to be human 
pathogens, performed well both in lyophilized and liquid-phase formats and with EBOV outbreak 
clinical samples. 
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 3 
Background (2577 words) 4 
Members of marburgvirus and ebolavirus genera in the family Filoviridae cause highly 5 
contagious illnesses with high mortality rate. There are five established species of ebolavirus: 6 
Zaire (EBOV), Bundibugyo (BDBV), Sudan (SUDV), Taï Forest (TAFV) and Reston 7 
(RESTV) viruses. All five can cause human infections, the first three have caused Ebola virus 8 
disease (EVD) outbreaks, TAFV has been associated with only one human case, whereas 9 
RESTV has been associated only with asymptomatic human seroconversions. Members of the 10 
Marburgvirus genus, consisting of the Marburg marburgvirus (MARV) and the Ravn virus 11 
(RAVV), also cause severe hemorrhagic fever in humans (Nyakarahuka et al. 2017). The third 12 
genus, Cuevavirus, is represented by the species Lloviu cuevavirus (LLOV), which hasn’t yet 13 
been associated with human infections (Negredo et al.  2011). Filoviruses are thought to be 14 
zoonotic, and bats are considered the likely reservoirs of these viruses (Olival et al., 2014). The 15 
Egyptian fruit bat, Rousettus aegypticus, has been identified as the host for MARV (Towner et 16 
al., 2009) while the very recently described Bombali ebolavirus (BOMV) and LLOV genome 17 
sequences were discovered in samples of insectivorous bats in Africa and Europe, respectively 18 
(Negredo et al., 2011; Goldstein et al., 2018). While the exact host of ebolaviruses has not been 19 
confirmed yet, genetic and serological evidence of ebolavirus infections have been detected in 20 
a few species of fruit bats and most recently  insectivorous bats (Leroy et al., 2005; Biek et al., 21 
2006; Swanepoel et al. 2007; Laing et al., 2018; Goldstein et al., 2018). Advances in virus 22 
discovery techniques have also yielded detection of novel marburg- and cuevaviruses in bats 23 
in China (He et al., 2015; Yang et al., 2017) thus expanding the known range of filoviruses.  24 
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The largest Ebola outbreak to date took place in 2014-2016 in both rural and urban areas of 25 
Guinea, Sierra Leone and Liberia in West Africa. It was caused by the EBOV, with more than 26 
28 000 reported cases, including more than 11 000 deaths (World Health Organization, WHO; 27 
http://www.who.int/csr/disease/ebola/en/). This epidemic highlighted the need for rapid 28 
detection of EBOV for disease containment.  In response, novel diagnostic tools have been 29 
developed for rapid and safe identification of EBOV (reviewed in Clark et al., 2018). The 30 
development of efficacious ring vaccination and new treatment modalities further requires 31 
efficient diagnostics. Most recently, the WHO reported a new epidemic of EBOV in the 32 
Democratic Republic of the Congo (DRC) in May 2018, and an unrelated outbreak some 33 
2500km away in DRC in July 2018 calling for swift response yet again. 34 
Between the EBOV outbreaks, a smaller outbreak of MARV occurred in Uganda in October, 35 
2017, emphasizing the need to develop preparedness to diagnose all filoviruses. Whereas many 36 
protocols have been developed recently for detection of EBOV, the detection methods covering 37 
the whole range of filoviruses still rely largely on the protocol by Panning et al., 2007. The 38 
discoveries of yet novel filoviruses (Goldstein et al. 2018) further underline the need to update 39 
and improve the preparedness for rapid and sensitive detection of filoviruses. 40 
Nucleic acid testing is the gold standard for filovirus diagnostics due to high viral loads that 41 
become detectable in just a few days after infection (Schurtleff et al. 2015). Such diagnostic 42 
tools need to be set up both at the site of the epidemic, and at sites of potential importation. 43 
The EBOV outbreak in West Africa activated a broad laboratory response e.g. in Europe 44 
(Reusken et al., 2018), with modern molecular diagnostics vastly available for detection of 45 
EBOV.  For example, freeze-dried PCR reagents would ease the transport and use of the assays 46 
in harsh field conditions at the site of epidemic.   47 
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Critical steps in nucleic acid testing are biosafe sample preparation and transport. Different 48 
protocols for the inactivation of ebolaviruses have been investigated, such as Qiagen AVL 49 
buffer and the MagNa Pure Lysis buffer (MPLB; Roche Life Science, Espoo, Finland). The 50 
protocol for sampling directly into MPLB has been suggested (Rosenstierne et al. 2016) and 51 
this would enable biosafe transport, which is challenging nowadays. Two widely used 52 
inactivators are Triton™-X 100, which interferes with lipid membranes, and lysis buffers 53 
containing guanidinium thiocyanate that lyse cells and inhibit nuclease activities. Neither of 54 
these can alone inactivate ebolaviruses, but parallel use of these two [e.g. Triton™-X 100 55 
together with AVL buffer from Viral RNA mini kit (Qiagen) or MPLB (Roche)] have been 56 
shown to fully inactivate ebolaviruses (Rosenstierne et al. 2016; Burton et al. 2017; van 57 
Kampen et al. 2017). WHO has recommended the parallel usage of two different inactivation 58 
reagents.  59 
 60 
Objectives 61 
Here we aimed to develop and evaluate a broad-range pan-filovirus detection method allowing 62 
early identification of the causative agent of a filovirus outbreak. We also evaluated the freeze-63 
dried and liquid formats, and possible effects that sample inactivation methods may have on 64 
the sensitivity of the assay. Finally, the method was put to test with a large panel of EVD 65 
outbreak patient samples.  66 
 67 
Study design 68 
Pan-filo L-RT-qPCR  69 
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Two different PCR reagents; Superscript® III Platinum® One-step qRT-PCR System 70 
(Invitrogen, Carlsbad, CA, USA; later referred as the Invitrogen assay) and lyophilized one-71 
step RT-qPCR reagents (Thermo Fisher Scientific, Massachusetts, USA; later referred as the 72 
Thermo-lyophilized assay) were used with the same primers, probes, and viral RNA panels. 73 
A pan-filo L-RT-qPCR targeting the L gene was developed and evaluated. For the assay, two 74 
separate reactions were carried out for each sample in the same run.  75 
In the first reaction, 160nM FAM-labelled Filo1 and Filo2 probes (adapted from Jääskeläinen 76 
et al. 2015; targeting ZEBOVs) in addition to ZEBOV/MARV reverse primers [480nM of 5ʼ-77 
AATGCATCCAATTAAAAACATTC-3ʼ (Jääskeläinen et al. 2015), 240nM of 5ʼ-78 
AATGCATCCARTCRAATAAATTY-3ʼ] and 240nM ZEBOV/MARV forward  primers [5ʼ-79 
AACTGATTTAGAGAAATACAATCTTGC-3ʼ (Jääskeläinen et al.2015),  5ʼ-80 
CTGATCTTGAGAAATACAACCTCGC-3ʼ, 5ʼ-81 
ACTGATYTAGAGAAATACAAYCTYGC-3ʼ], and 160nM VIC-labelled Filo3 and Filo4 82 
probes [VIC- TTT ACA CGR CAT TTC ATA GAC T-MGBNFQ and VIC- ACT GTA ATC 83 
GAT GTT ATG GT-MGBNFQ; mainly targeting MARVs] were used with final 84 
concentration of 2mM MgSO4.  85 
In the second reaction, a final concentration of 240nM of BDBV-RV primer [5ʼ-86 
AATGCATCCAATTGAATAAATTT-3ʼ], 240nM SUDV-RV [5ʼ-87 
CATCCAATCAAAGACATTGC-3ʼ], 320nM FILO-FW [5ʼ-88 
ACMGACCTRGARAAATAYAACYTGGC-3ʼ] in addition to 160nM FAM-labelled Filo5-89 
probe [FAM- ATG AGT TTA CAG CTC CAT T-MGBNFQ; mainly BDBVs] and 160nM 90 
VIC-labelled Filo6 probe [VIC- TCA TCA AAT ATT GCA ACC AA-MGBNFQ; mainly 91 
targeting SUDVs] were used.  92 
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The Invitrogen assay in the Mx3005P qPCR System (Agilent Technologies Finland Oy, Espoo, 93 
Finland) was initially used to optimize the concentrations of the primers and probes. Both 94 
Invitrogen and Thermo-lyophilized assays were further tested by screening of different 95 
filoviruses, and to verify the specificity, and to test the PCR reagent ability to tolerate the 96 
inhibition effect of Triton™-X 100 (Sigma-Aldrich, Espoo, Finland), MPLB (Roche), and 97 
AVL lysis buffer (Qiagen, Hilden, Germany). Finally, the limits of detection (LODs) were 98 
determined for the Thermo-lyophilized assay.  99 
The RT-qPCR running protocol for Invitrogen-liquid assay was adapted from the EBOV assay 100 
described in Jääskeläinen et al. (2015) and 7µl of template was used, and the protocol for 101 
Thermo-lyophilized assay 3.6µl of template was used and the run was carried out as follows: 102 
reverse transcription for 10 min at 45ºC, PCR initial activation step for 10 min at 95ºC followed 103 
by 50 cycles of denaturation for 15s at 95ºC, and annealing and extension for 70s at 60ºC. 104 
 105 
Viral controls 106 
Quantified in vitro RNAs were produced using constructs for EBOV and MARV L genes 107 
(described in Jääskeläinen et al. 2015), in addition to synthetized L-gene constructs of SUDV 108 
and BDBV ebolaviruses (GeneArt™ Plasmid Construction Service, Thermo Fischer 109 
Scientific). RNAs from inactivated whole virus controls of EBOV/Guinea C05 and 110 
EBOV/Mayinga, MARV/Angola, RAVV, SUDV/Boniface, BDBV/E76, TAFV/Ivory Coast 111 
and RESTV were obtained from Public Health England (PHE, Porton Down, Salisbury, UK).  112 
These viruses were cultivated in Vero E6 cells, inactivated, and RNA extracted using QIAamp 113 
Viral RNA Mini kit (Qiagen, Hilden, Germany) according to manufacturer's instruction. 114 
 115 
Specificity and inhibition tests 116 
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For assessing specificity, EDTA-blood samples from 45 individuals that were sent for routine 117 
human herpesvirus 6 nucleic acid testing (later referred as HU-samples) in Helsinki University 118 
Hospital (HUSLAB, Helsinki, Finland; anonymous samples, research permit TYH2017257), 119 
were extracted using MagNa Pure 96 automated system and nucleic acid kits (MPLB lysis; 120 
Roche Life Science, Espoo, Finland), and tested using the Invitrogen and Thermo-lyophilized 121 
assays. In addition, for testing other viral hemorrhagic fever agents, the RNAs from inactivated 122 
whole virus controls of Lassa virus (strain Liberia; LASV), Dengueviruses 1-4 (DENV1-4), 123 
Yellow fever virus (strain 17D; YFV), Rift Valley fever virus (strain RKI; RVFV) and 124 
Crimean-Congo hemorrhagic virus (strain Hoti; CCHFV) were extracted using QIAamp Viral 125 
RNA Mini kit (Qiagen) (Table 1).  126 
For Triton™-X 100 (Sigma-Aldrich, Espoo, Finland) inhibition tests, excess amount of 127 
Triton™-X 100 was added to EDTA-blood samples in final volume of 10% in order to test any 128 
PCR inhibition effect due to the reagent in both Invitrogen and Thermo-lyophilized assays. 129 
Triton-treated (10 min at room temperature) EDTA-blood samples were extracted using AVL 130 
and QIAamp Viral RNA Mini kit (Qiagen). In addition, EDTA-blood samples without extra 131 
Triton treatment were extracted using MPLB and MagNA Pure extraction system (Roche). 132 
Different amounts of EBOV, MARV, SUDV or BDBV RNAs were spiked in the extracted 133 
samples, and both Thermo-lyophilized and Invitrogen assays were carried out (Figure 1).  134 
 135 
Sensitivity 136 
Sensitivity of the pan-filo L-RT-qPCR was tested using the Thermo-lyophilized assay and 137 
serial dilutions of quantified RNA transcripts (Qubit, Thermo Fisher Scientific) of EBOV, 138 
MARV, SUDV and BDBV L-gene, and TAFV (PHE, quantified). Five parallel reactions and 139 
Probit Regression (SPSS, IBM) were used to determine LODs. The Invitrogen assay was tested 140 
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in parallel with the WHO-approved RealStar® Filovirus RT-PCR Kit (Altona Diagnostics 141 
GmbH, Hamburg, Germany) using ZEBOV strain Guinea (range 5-1000 genome copies/PCR 142 
reaction; PHE), SUDV L-gene RNA (range 7-1.5E6 genome copies/PCR reaction) and BDBV 143 
L-gene RNA (range 13-1.25E6 genome copies/PCR reaction) (Table 1).  In addition, whole 144 
virus controls (Table 1, PHE) were tested to screen different filovirus targets.   145 
 146 
Screening of Ebola patient samples 147 
Samples were collected in Guinea between December 2014 and May 2015 as part of the 148 
Institute Pasteur de Dakar (IPD) diagnostics activities of suspected EVD cases (under an 149 
emergency response mandate from the government of Guinea and WHO, ref 150 
0235/14/GUI/CPC; all patients agreed to be tested for Ebola virus infection and leftover 151 
samples to be used for further investigations). Suspect Ebola patients were defined as any 152 
person with recent or past sudden onset of fever and having been in contact with a suspected, 153 
probable or confirmed case of EVD, or any person with sudden onset of fever and at least three 154 
of the following symptoms: headaches, anorexia/loss of appetite, lethargy, myalgia, arthralgia, 155 
breathing difficulties, or any person with inexplicable bleeding. Eighty-three serum samples 156 
from acute cases were extracted using QIAamp Viral RNA Mini kit (Qiagen) according to 157 
manufacturer´s instructions in IPD, Senegal. These were all EBOV nucleic acid positive using 158 
the reference EBOV NP-RT-qPCR (Weidmann et al. 2004; using modified forward primer of 159 
5ʼ-ATGATGGARGCTACGGCG-3ʼ and probe 5ʼ-CARAGTTACTCGGAAAACGGCAT) 160 
with viral loads ranging from 5 RNA copies to 5.5 million RNA copies per reaction. In IPD, 161 
the pan-filo L-RT-qPCR and EBOV NP-RT-qPCR were carried out in parallel using 162 
QuantiTect® Probe RT-PCR kit (Qiagen) and 5µl of template for performance comparison.   163 
 164 
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Results 165 
Both Invitrogen and Thermo-lyophilized pan-filo L-RT-qPCR assays tested negative for HU-166 
samples (N=45), as well as for LASV, DENV1-4, YFV, RVFV and CCHFV, indicating 167 
analytical specificity of 100% (95CI: 94.8-100%; Table 1). In addition, both assays detected 168 
EBOV/Guinea C05, EBOV/Mayinga, MARV/Angola, RAVV, SUDV/Boniface, BDBV/E76, 169 
TAFV/Ivory Coast and RESTV (Table 1).  170 
The LODs (SPSS, Probit, 95CI) for Thermo-lyophilized assay were 9.9 copies/PCR reaction 171 
for MARV, 9.4 for EBOV, 65 for BDBV, 1151 for SUDV and 289 for TAFV (PHE).  172 
The Invitrogen pan-filo L-RT-qPCR assay was as good as the RealStar® Filovirus Screen RT-173 
PCR Kit for EBOV, however, for BDBV and SUDV samples there were minor differences 174 
(Table 1).  175 
Triton™-X 100 (Sigma-Aldrich), AVL (Qiagen) or MPLB (Roche) did not interfere the 176 
Invitrogen or Thermo-lyophilized one-step assays (Figure 1).   177 
All of the patient samples tested (83) from IPD (Senegal) were positive for EBOV nucleic acids 178 
using our pan-filo L-RT-qPCR assay and EBOV NP-RT-qPCR (Figure 2) indicating 100% 179 
analytical sensitivity. The LOD for EBOV NP-RT-qPCR was 4 copies/PCR reaction (tested in 180 
University of Helsinki; SPSS, Probit, 95CI). 181 
 182 
Discussion  183 
Filoviruses were first isolated more than 50 years ago, and outbreaks with high mortality have 184 
subsequently been caused by four viruses, MARV (9 times) SUDV (5 times), BDBV (twice) 185 
and EBOV (14 times) (WHO). For containing and restricting the epidemics, including 186 
establishing control measures and therapeutics, accessible, rapid and reliable diagnostic tests 187 
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are essential. IgM and IgG detection assays are used to confirm resolved disease or to 188 
diagnostically monitor samples of cases beyond the diagnostic window for molecular detection. 189 
While rapid antigen detection tests with varying sensitivity and specificity have been developed 190 
for EBOV detection [Walker et al., 2015; Broadhurst et al. 2015], nucleic acid detection 191 
remains the cornerstone of diagnostics. It is a challenge to find simple protocols, particularly 192 
primer and probe sequences applicable to all pathogenic filoviruses, yet tests covering all 193 
filoviruses would be essential in early identification of outbreaks as well as occasional cases in 194 
endemic regions or travelers. Adding such a test and its evaluation is what we report here. 195 
However, in future, the lyophilized protocol would benefit from lyophilized primers and probes 196 
in mastermixes making the protocol more suitable for field conditions.  197 
 198 
After the West African EBOV epidemic, a variety of methods, inactivation protocols and 199 
handling procedures have been studied (Rosenstierne et al. 2016; Burton et al. 2017; van 200 
Kampen et al. 2017). Most of the detection methods, however, have been based on the detection 201 
of only EBOV nucleic acids, and this limitation can cost time for diagnosis of other filoviruses. 202 
At the moment there is only one commercial pan-filovirus kit (RealStar® Filovirus Screen RT-203 
PCR Kit) approved by WHO that also detects MARV, others still aim to detect EBOV antigen 204 
or nucleic acids (WHO; http://www.who.int/medicines/ebola-205 
treatment/emp_ebola_diagnostics/en/). These WHO-approved tests include Liferiver™ Ebola 206 
Virus (EBOV) Real Time RT-PCR kit (Shanghai ZJ BioTech Co., Ltd) which can be used for 207 
detection EBOV, SUDV, TAFV, BDBV, and Xpert® Ebola Test (Cepheid AB, Sweden), 208 
FilmArray™ Biothreat-E (BioFire Defence LLC, USA) which both only detect EBOV.  209 
The 2-well pan-filo L-RT-qPCR assay described here detected all the tested strains of MARV, 210 
EBOV, BDBV, SUDV, TAFV, as well as RESTV. In addition, we were able to validate the 211 
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pan-filo L-RT-qPCR assay with clinical samples from the West-African EBOV outbreak with 212 
excellent performance. Overall, the assay achieved better performance for EBOV and MARV 213 
than rest of the tested targets, but was still at the same level as WHO-approved RealStar® 214 
Filovirus Screen RT-PCR kit. With this in mind, it´s recommended to test several samples from 215 
patient suspected for VHF to avoid false negative results at the early onset of disease. 216 
The specificity was 100%, and the lyophilized or liquid assays were not affected by common 217 
chemical inactivation reagents, i.e. MPLB, AVL or Triton™-X 100. These results are in line 218 
with Rosenstierne et al. (2016) who tested MPLB and AVL buffers.  219 
Based on the sequences, the pan-filo L-RT-qPCR primers and probes are not a perfect match 220 
for BOMV (MF319185; forward primer 4, reverse 2, and VIC-probe 3 mismatches) or other 221 
bat-related filoviruses in GenBank (National Center for Biotechnology Information, USA). 222 
However, when screening Kenyan bat samples, with the pan-filo L-RT-qPCR we detected one 223 
sample positive for filovirus. The bat-related filovirus was later sequenced and identified as 224 
BOMV (Forbes et al., Emerging Infectious Diseases 2019, in press).  225 
We conclude that the developed assays, both lyophilized and liquid phase, can be used 226 
effectively to screen samples from patients suspected for any known filoviral hemorrhagic 227 
fever, and both marburg and ebolaviruses can be detected.  228 
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Figure 1a and b. Comparing the performance of the pan-filo L-RT-qPCR using Thermo-
lyophilized and Invitrogen-liquid assays for potential inhibitory effects of different reagents 
and inactivation methods [Fig 1a.,Triton™-X 100 treatment (Triton) or Fig 1b. Magna Pure 
Lysis buffer (MPLB)]. 
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Ex, 10-x (E1=10-1, E2=10-2…) dilution, single replicate; MARV L, L gene construct of Marburg 
virus; ZEBOV Guinea, RNA extract of Zaire ebolavirus; BDBV L, L gene construct of 
Bundibugyo virus; SUDV L, L gene construct of Sudan ebolavirus; negat, negative. 
Triton: EDTA-blood Triton™-X 100 treated and extracted using Qiagen kit, spiked with 
filoviral RNA 
MPLB: EDTA-blood, Magna Pure LC extracted, using Magna Pure Lysis buffer, spiked with 
filoviral RNA 
Over Ct 40 results are not considered real positive until confirmed by another test if used in 
diagnosis of filoviral disease in clinical settings. Here Ct-values are listed due to the 
comparison purposes.   
 Figure 2. Parallel results of pan-filo L-Rt-qPCR (this study) and EBOV NP-RT-qPCR (Weidmann et al. 2004) assays. The RNA copy numbers (5 
copies to 5.5 million copies) of EVD patient samples are presented in the X-axis (logarithmic scale, log10) and Ct values in the Y-axis. R
2, R-
squared.      
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Panel/sample 
material 
Microbial agent No of 
samples/tests, 
neg/pos 
Pan-filo L-RT-qPCR assays: Results from Liquid and 
Lyophilized platforms compared 
neg for 
FILO 
RNA  
pos 
for 
FILO 
RNA 
neg for 
FILO RNA 
pos for 
FILO RNA 
Liq 
(Invitrogen) 
Lyo 
(Thermo) 
Liq 
(Invitrogen) 
Lyo 
(Thermo) 
NEG: 
Whole blood1 
Negative sample panel 45 - 45/45 45/45 0/45 0/45 
Total  45 - 45/45 45/45 0/45 0/45 
NEG: 
Viruses2 
YFV (strains 17D) 3 - 3/3 3/3 0/3 0/3 
DENV1 (RKI) 3 - 3/3 3/3 0/3 0/3 
DENV2 (RKI) 3 - 3/3 3/3 0/3 0/3 
DENV3 (RKI) 3 - 3/3 3/3 0/3 0/3 
DENV4 (RKI) 3 - 3/3 3/3 0/3 0/3 
LASV (strain Liberia, RKI) 3 - 3/3 3/3 0/3 0/3 
RVFV (strain RKI, RKI) 3 - 3/3 3/3 0/3 0/3 
CCHFV (strain Hoti, RKI) 3 - 3/3 3/3 0/3 0/3 
Total  24 - 24/24 24/24 0/24 0/24 
All FILO negatives 69/69 (100%; 95CI 94.8-100%) 
POS: 
Viruses/Viral 
RNAs 
ZEBOV (strain Mayinga, 
PHE) 
- 3 0/3 0/3 3/3 3/3 
MARV (strain Angola) - 2 0/2 0/2 2/2 2/2 
MARV (strain Ravn) - 2 0/2 0/2 2/2 2/2 
SUDV strain Boniface - 2 0/2 0/2 2/2 2/2 
BDBV strain E76 - 2 0/2 0/2 2/2 2/2 
Taï Forest virus strain Ivory 
Coast*  
- 2 0/2 0/2 2/2 2/2 
Reston virus - 2 0/2 0/2 2/2 2/2 
MARV L-gene RNA (HU)* - 15 0/15 0/15 15/15 15/15 
Table 1. Sample panels, materials and viruses used for validation of both liquid and lyophilized 
assay formats of the pan-filo L-RT-qPCR, and the results of the validation.  
POS, positive; NEG, negative; FILO, filoviruses; rxn, reaction; ND, not determined; ZEBOV, Zaire 
ebolavirus; MARV, Marburg virus; BDBV, Bundibugyo virus; SUDV, Sudan ebolavirus; HU, 
University of Helsinki; PHE, Public Health England; RKI, Robert Koch Institute; DENV, 
ZEBOV L-gene construct 
RNA (HU) 
- 15 0/15 0/15 15/15 15/15 
Total  - 45 0/45 0/45 45/45 45/45 
POS: 
38 viral 
controls tested 
using 
RealStar® 
Filovirus RT-
PCR Kit 3 and 
Invitrogen 
assay 
Virus Reference test: RealStar® Filovirus  
5 parallel rxns, mean Ct (±SD)  
Liq, Invitrogen  
5 parallel rxns, mean Ct 
(±SD)  
ZEBOV (strain Guinea, 
PHE)*; 100 copies/rxn 
5/5, Ct 30.3 (±0.31) 5/5, Ct 35.6 (±0.66) 
50 copies/rxn 5/5, Ct 32.3, (±2.7) 4/5, Ct 36.2 (±0.9) 
25 copies/rxn 1/5, Ct 34.3 (ND) 1/5, Ct 36.1 (ND) 
Total ZEBOV 11/15 10/15 
SUDV L-gene (GeneArt),  
1500 copies/rxn 
5/5, Ct 31.3 (±3.5) 5/5, Ct 38.3 (±1.3) 
150 copies/rxn 2/5, Ct 33.7 (±3.8) 1/5, Ct 38.8 (ND) 
15 copies/rxn 0/5 0/5 
Total SUDV 7/15 6/15 
BDBV L-gene 
(GeneArt)**,  
1250; 625; 125 copies/rxn  
1250: Ct 31.4 (ND);  
625: Ct 32.0 (ND);  
125:Ct 35.4 (ND) 
1250: Ct 33.4 (ND),  
625: Ct 36.5 (ND),  
125: Ct 36.3 (ND)  
62.5 copies/rxn 1/5, Ct 30 (ND) 4/5, Ct 38.1 (±1.4) 
Total BDBV 4/8 7/8 
Altogether 22/38 23/38 
denguevirus; LASV, Lassa virus; YFV, yellow fever virus; CCHFV, Crimean-Congo Hemorrhagic 
virus; RVFV, Rift-Valley Fever virus. 
** Only one reaction was carried out.  
1EDTA-Blood samples (Helsinki University Hospital, HUSLAB, Finland) 
2RNA extractions from inactivated virus cultivations kindly provided by Prof. Niedrig (Robert Koch 
Institute, Germany).  
3 RealStar® Filovirus Screen RT-PCR Kit (altona Diagnostics GmbH, Hamburg, Germany). Only 
liquid phase Invitrogen pan-filo L RT-qPCR assay was carried out parallel with RealStar® Filovirus 
Screen RT-PCR Kit.  
